Catalyst Biosciences Lands $40,400,000 Series C Round

  • Feed Type
  • Date
    12/3/2008
  • Company Name
    Catalyst Biosciences
  • Mailing Address
    260 Littlefield Avenue South San Francisco, CA 94080
  • Company Description
    Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of proteases.
  • Website
    http://www.catalystbiosciences.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $40,400,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The financing provides us with several years of funding that will allow us to build our pipeline of Alterase therapeutics including advancing our lead protease, CB 813, an improved factor VIIa product for the treatment of acute bleeding in hemophiliacs, through Phase 1/2 proof-of-concept studies in patients.
  • M&A Terms
  • Venture Investor
    Essex Woodlands Health Ventures
  • Venture Investor
    Burrill & Company
  • Venture Investor
    HealthCare Ventures
  • Venture Investor
    Johnson & Johnson Development Corporation
  • Venture Investor
    Morgenthaler Ventures
  • Venture Investor
    Novartis BioVenture Fund

By posting a comment, you agree to our terms and conditions.